Grifoni E, et al. - Peripheral artery disease (PAD) patients undergoing percutaneous transluminal angioplasty (PTA) were investigated for the degree of on-treatment platelet reactivity, and its association with ischaemic and haemorrhagic adverse events at follow up. Researchers performed an observational, prospective, single centre study including 177 consecutive patients with PAD undergoing PTA. Treatment included dual antiplatelet therapy with aspirin and a P2Y12 inhibitor. Observations revealed a high prevalence of on-clopidogrel and aspirin high platelet reactivity, which was noted to have a significant correlation with the risk of death. Conversely, a higher risk of bleeding was observed in association with a low on-clopidogrel platelet reactivity. Hence results demonstrate that in PAD patients, the entity of platelet inhibition is associated with both thrombotic and bleeding complications.